Dec 22 (Reuters) - Johnson & Johnson (NYSE:JNJ) JNJ.N :
* JANSSEN ANNOUNCES HEALTH CANADA APPROVAL OF DARZALEX®* COMBINATION REGIMEN FOR NEWLY DIAGNOSED, TRANSPLANT-ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA
* JANSSEN PHARMACEUTICAL - HEALTH CANADA APPROVED DARZALEX COMBINATION REGIMEN FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR ASCT